Breckenridge Brewery Opens New Location in Fort Collins, Colorado
Newsfilter· 2024-08-05 19:00
FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000- square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholdin ...
FactSet Declares Dividend
Newsfilter· 2024-08-05 19:00
NORWALK, Conn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved a regular quarterly cash dividend of $1.04 per share. The cash dividend will be paid on September 19, 2024, to holders of record of FactSet's common stock at the close of business on August 30, 2024. About FactSet FactSet (NYSE:FDS | NASDAQ:FDS) helps the financial community to see more, think bigger, ...
Labcorp Finalizes Acquisition of Select Assets of Invitae
Prnewswire· 2024-08-05 19:00
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C., Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
Prnewswire· 2024-08-05 19:00
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected ...
Steakholder Foods® to Present at Sidoti Micro-Cap Virtual Investor Conference
Newsfilter· 2024-08-05 19:00
Presentation to be Webcast at 9:15 AM ET on August 14, 2024 Rehovot, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH), a leading innovator in alternative proteins and 3D printing technologies, today announced its Chief Executive Officer, Arik Kaufman, will host a presentation followed by one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on August 14-15, 2024. The presentation will begin at 9:15 AM ET on Wednesday, August 14, 2 ...
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
Newsfilter· 2024-08-05 19:00
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a ...
Timken to Expand Motion-Control Platform, Capabilities with Acquisition of CGI Inc.
Prnewswire· 2024-08-05 18:51
Addition will create unmatched portfolio of precision drives NORTH CANTON, Ohio, Aug. 5, 2024 /PRNewswire/ -- The Timken Company (NYSE: TKR;www.timken.com), a global technology leader in engineered bearings and industrial motion, has agreed to acquire CGI Inc., a Nevada-based manufacturer of precision drive systems serving a broad range of automation markets with a concentration in medical robotics. The deal is subject to customary closing conditions, including regulatory approval, and is expected to close ...
Kennametal Announces David Bersaglini as President of Metal Cutting Segment
Prnewswire· 2024-08-05 18:45
PITTSBURGH, Aug. 5, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced that David Bersaglini will join the company as Vice President of Kennametal Inc. and President of the Metal Cutting segment, effective August 26, 2024. Bersaglini has nearly 25 years of experience and comes to the company from Copeland, a spin-off of Emerson, where he was Vice President and General Manager of Global Refrigeration. "Dave brings a strong track record of success to Kennametal, with extensive experience leading ...
IGT Partners with Monarch Casino & Resort Inc. for Sports Betting Expansion in Nevada and Colorado
Prnewswire· 2024-08-05 18:45
Atlantis Casino Resort Spa and Monarch Casino Resort Spa are the latest gaming venues to power retail and mobile sports betting with IGT PlaySports technology LONDON, Aug. 5, 2024 /PRNewswire/ -- International Game Technology PLC ("IGT") (NYSE: IGT) announced today that it expanded its sports betting footprint in Nevada and Colorado through an IGT PlaySports™ technology and services agreement with Monarch Casino & Resort, Inc. (Nasdaq: MCRI). Per the agreement, the award-winning IGT PlaySports platform and ...
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
Newsfilter· 2024-08-05 18:30
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OC ...